Compound B as angiogenic agent in combination with human growth factors

1. A pharmaceutical composition for promoting angiogenesis, comprising Component B and a human growth factor selected from the group consisting of bFGF and VEGF, in combination with a pharmaceutically acceptable carrier, wherein the ratio of the amount of said Component B to the amount of said human growth factor is selected to provide synergistic angiogenesis results when administered to a patient in need thereof.

2. A method for promoting angiogenesis in a patient in need thereof, comprising administering to the patient Component B and a human growth factor selected from the group consisting of bFGF and VEGF, for a time sufficient and in amounts effective for the promotion of angiogenesis in the patient, wherein said Component B and said human growth factor are administered such that they will be simultaneously present in the blood of the patient in amounts effective for the synergistic promotion of angiogenesis in the patient.

3. The method of claim 2 , wherein the angiogenesis is in relation to the treatment of a wound, ulcer or other traumatic lesion to the tissues of the body of the patient.

4. The method of claim 2 , wherein the Component B and the human growth factor are administered in a single composition.

5. The method of claim 3 , wherein the Component B and the human growth factor are administered in a single composition.

6. The method of claim 2 , wherein the Component B and the human growth factor are administered in separate compositions.

7. The method of claim 3 , wherein the Component B and the human growth factor are administered in separate compositions.

8. The method of claim 2 , wherein the ratio of the amount of Component B to the amount of the human growth factor is selected to provide synergistic angiogenesis results.

9. A pharmaceutical composition for treating a wound, ulcer, or other traumatic lesion, comprising Component B and a human growth factor selected from the group consisting of bFGF and VEGF, in combination with a pharmaceutically acceptable carrier, wherein the ratio of the amount of said Component B to the amount of said human growth factor is selected to provide synergistic results when administered to a patient in need thereof.

10. A method of treating a wound, ulcer, or other traumatic lesion in a patient in need thereof, comprising administering the patient Component B and a human growth factor selected from the group consisting of bFGF and VEGF, for a time sufficient and in an amount effective for the treatment of the wound, ulcer or other traumatic lesion in the patient, wherein said Component B and said human growth factor are administered such that they will be simultaneously present in the blood of the patient in amounts effective for the synergistic treatment of the wound, ulcer or other traumatic lesion in the patient.

11. The method of claim 10 , wherein the Component B and the human growth factor are administered in separate administration doses.

12. The method of claim 10 , wherein the ratio of the amount of Component B to the amount of the human growth factor is selected to provide synergistic results.